Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 162 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]
2.Enlace a cita original Cita con resumen
Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]
3.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
7. Cita con resumen
Inghammar M, Svanström H, Melbye M, Pasternak B, Hviid A. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ 2016;352:i843. [Ref.ID 100141]
8. Cita con resumen
Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]
9.Tiene citas relacionadas Cita con resumen
Li B-Z, Threapleton DE, Wang JY, Xu J-M, Yuan J-Q, Zhang C, Li P, Ye Q-L, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015;351:h4052. [Ref.ID 99413]
10. Cita con resumen
Kaji AH, Lewis RJ. Noninferiority trials: is a new treatment almost as effective as another?. JAMA 2015;313:2371-2. [Ref.ID 99295]
11.Tiene citas relacionadas Cita con resumen
Salminen P, Paajanen H, Rautio T, Nordström P, Aarnio M, Rantanen T, Tuominen R, Hurme S, Virtanen J, Mecklin J-P, Sand J, Jartti A, Rinta-Kiikka I, Grönroos JM. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: the APPAC randomized clinical trial. JAMA 2015;313:2340-8. [Ref.ID 99294]
12.Tiene citas relacionadas Cita con resumen
Livingston EH, Vons C. Treating appendicitis without surgery. JAMA 2015;313:2327-8. [Ref.ID 99293]
14.Tiene citas relacionadas Cita con resumen
Chan JF-W, Yuen K-Y. A new ASPECT for complicated urinary tract infections. Lancet 2015;385:1920-2. [Ref.ID 99150]
15. Cita con resumen
Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics 2014;134:e146-153. [Ref.ID 97690]
16. Cita con resumen
Rao GA, Mann JR, Shoaibi A, Lee Bennett C, Nahhas G, Sutton SS, Jacob S, Strayer SM. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014;12:121-7. [Ref.ID 97224]
17.
Anónimo. Drugs for urinary tract infections. JAMA 2014;311:855-6. [Ref.ID 97160]
18. Cita con resumen
Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon injury and fluoroquinolone use: a systematic review. Drug Saf 2013;36:709-21. [Ref.ID 96211]
20. Cita con resumen
Kuehn BM. FDA warning and study highlight fluoroquinolone risks. JAMA 2013;310:1014. [Ref.ID 96081]
Seleccionar todas
 
 1 a 20 de 162 siguiente >>